Tumor Suppression Activity Of Ginsenoside Rg₃ On Human Colon Cancer Cell Line HCE8693

To find a new way to treat caner using traditional Chinese medicine and modern gene therapy, we evaluate the therapeutic efficiency of ginsenoside Rg3, the therapeutic efficiency of ginsenoside Rg3 combined with TRAIL gene on human colon cancer cell line HCE8693 .MethodsHuman colon cancer cell line HCE8693 was transfected with adenovirus-mediated TRAIL gene Ad/GT-TRAIL and TRAIL/ ginsenoside Rg3 combination. Cell growth and apoptosis were measured by MTT method and flow cytometry.ResultsThe cell line HCE8693 was either suppressed by a higher concentration (0.01%, 0.017%, 0.025%, 0.05%) of ginsenoside Rg3 or by TRAIL gene in 2000 MOI. The suppression percentages were 8.6%, 8.6%, 18.7%, 21.9% and 24.3% respectively, and the apoptic percentage were 5.4%, 7.6%, 20.3%, 20.9% and 23.2% respectively. Combined with ginsenoside Rg3, the suppression and the apoptosis of cell line HCE8693 could be significantly enhanced by TRAIL gene. The suppression and the apoptic percentage reached 17.8%, 25.7%, 37.3%, 46.2% and 18.9% , 20.1%, 46.2%, 56.0% respectively.ConclusionA higher concentration of ginsenoside Rg3 or TRAIL gene was able to induce apoptosis and suppress the growth of human colon cancer cell line HCE8693. Combined with ginsenoside Rg3 and TRAIL, the suppression and apoptosis could be significantly enhanced. Ginsenoside Rg3 inhibits the growth of HCE8693 and induce apoptosis in a dose-dependent manner.